Both PRP and HA have been widely used to improve lubrication, modulate inflammation, and modify the joint catabolic microenvironment, with the goal of not only reducing clinical symptoms but also slowing the progression of OA.
When PRP and HA are used in combination, these effects are increased and prolonged. HA creates a bioactive scaffold on which platelets progressively release their growth factors. RegenPRP does not negatively affect the mechanical, elastic or viscous properties of HA.
ADVANTAGES OF THE TECHNOLOGY
- Standardized user-independent preparation.
- Minimum blood volume required.
- Secure closed loop system.
- Mechanical isolation of PRP using a biologically inert gel after a 5-minute centrifugation.
- Reversible anticoagulation with a pharmaceutical grade sodium citrate solution at pH 7.
- Minimal learning curve and ease of use.
- Operationally and clinically efficient process.
- Facilitates and speeds up routine practice.
CELLULAR MATRIX PLATFORM
- Certified technology for the preparation of RegenPRP® combined with hyaluronic acid (HA) (CM-PRP-HA).
- Contains 2 ml of non-cross-linked HA at a concentration of 20 mg/ml (40 mg total).
- HA is produced by bacterial fermentation, so it does not contain animal proteins.
SCIENTIFIC ADVANTAGES OF REGENPRP®
- Proven safety and effectiveness.
- Evidence-based results for numerous therapeutic indications.
- Large number of clinical studies, with more than 200 publications.
BIOLOGICAL ADVANTAGES
- RegenPRP® is standardized, reduced in leukocytes and easily reproducible.
- Regen Lab’s specific separating gel technology ensures minimal variability.
- Platelet recovery in CM-PRP-HA >70%.
- High platelet quality.
- Viable and functional platelets.
- Complete plasma recovery.
- Without loss of plasma growth factors and fibrinogen.
- Reduced leukocytes PRP Depletion ~94.3% of pro-inflammatory granulocytes, leaving mainly lymphocytes and monocytes.
- There are practically no red blood cells.
- Depletion of ~99.5% of erythrocytes.
